Edoardo Crimini is in his fourth year of residency in medical oncology at the University of Milan, Milan, Italy and works at the European Institute of Oncology, Milan under the mentorship of Professor Giuseppe Curigliano.
As a visiting student at the Fox Chase Cancer Center, Philadelphia, PA, USA, he worked on research concerning new prognostic markers of renal cell carcinoma and immunophenotypic characterisation of natural killer cells in multiple myeloma. Throughout his professional and academic career, Dr Crimini’s research has centred on early-phase clinical trials in precision oncology and breast cancer patient care. He has authored or contributed to more than 30 publications in these fields.
In addition to his published work, Dr Crimini has contributed to the molecular tumour board at the European Institute of Oncology, an initiative that sought to enable use of the ESMO Scale for Clinical Actionability of Molecular Targets and precision oncology to improve clinical outcomes.
